Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary b cells into malignant cells

Haematologica

Volumn 96, Issue 9, 2011, Pages 1318-1326

  Nakagawa, Masao ^a   Tsuzuki, Shinobu ^a   Honma, Keiichiro ^a   Taguchi, Osamu ^a   Seto, Masao ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Bcl2; Ccnd1; Cooperative genes; Malignant transformation; Myc; Oncogenes

Indexed keywords

COMPLEMENTARY DNA;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BCL 2 GENE; CANCER CELL; CARCINOGENICITY; CCND1 GENE; CELL CULTURE; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; DNA LIBRARY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NRAS GENE; ONCOGENE MYC; RETROVIRUS INFECTION;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, SCID; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TUMOR STEM CELL ASSAY;

EID: 80052375259     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.041053     Document Type: Article

References (42)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-99.
2. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580-94.
3. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood. 1995;86(10): 3905-14.
4. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(2):233-7.
5. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factorsassociated with survival. Blood. 2009;114 (11):2273-9.
6. Kluin PM, Harris NL, Stein H, Leoncini L. Bcell lymphoma, unclassifiable, with features intermediate between diffuse large Bcell lymphoma and Burkitt lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France: IARC; 2008:265-266, Chapter 10
7. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans H, Boerma EJ, et al. Double hit B-cell lymphomas. Blood. 2011;117(8):2319-31.
8. De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, Kluin PM. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med. 1988;318(21):1373-8.
9. Lee JT, Innes DJ Jr, Williams ME. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest. 1989;84(5):1454-9.
10. Thangavelu M, Olopade O, Beckman E, Vardiman JW, Larson RA, McKeithan TW, et al. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990;2(2):147-58.
11. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992;80(3):758-67.
12. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA. 2002;99 (13):8886-91.
13. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 1999;59(7 Suppl):1685s-1692s
14. Kawakami K, Miyanishi S, Sonoki T, Nakamura S, Nomura K, Taniwaki M, et al. Case of B-cell lymphoma with rearrangement of the BCL1, BCL2, BCL6, and c-MYC genes. Int J Hematol. 2004;79(5):474-9.
15. Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C. Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms. Genes Chromosomes Cancer. 2011;50(1): 43-50.
16. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-19.
17. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647-56.
18. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2(10):764-76.
19. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;448(7152):445-51.
20. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298-306.
21. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189 (9):1399-412.
22. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, et al. Retrovirusmediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31(11):1007-14.
23. Rolink A, Kudo A, Karasuyama H, Kikuchi Y, Melchers F. Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo. Embo J. 1991;10(2):327-36.
24. Ogawa M, Nishikawa S, Ikuta K, Yamamura F, Naito M, Takahashi K, et al. B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. Embo J. 1988;7(5): 1337-43.
25. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci USA. 2004;101(22):8443-8.
26. Kamiya A, Kakinuma S, Onodera M, Miyajima A, Nakauchi H. Prospero-related homeobox 1 and liver receptor homolog 1 coordinately regulate long-term proliferation of murine fetal hepatoblasts. Hepatology. 2008;48(1):252-64.
27. Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 2001; 98(9):2837-44.
28. Wlodarska I, Dierickx D, Vanhentenrijk V, an Roosbroeck K, Pospisilova H, Minnei F, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111(12):5683-90.
29. Kasugai Y, Tagawa H, Kameoka Y, Morishima Y, Nakamura S, Seto M. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res. 2005;11(23):8265-72.
30. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185 (2):159-66.
31. Suzuki R, Kuroda H, Komatsu H, Hosokawa Y, Kagami Y, Ogura M, et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia. 1999;13(9): 1335-42.
32. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res. 2002;8(3):729-33.
33. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-97.
34. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315-21.
35. Ciemerych MA, Kenney AM, Sicinska E, Kalaszczynska I, Bronson RT, Rowitch DH, et al. Development of mice expressing a single D-type cyclin. Genes Dev. 2002;16(24):3277-89.
36. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell. 2004;118(4):477-91.
37. Alexander WS, Bernard O, Cory S, Adams JM. title typecontributorLymphomagenesis in E mu-myc transgenic mice can involve ras mutations/title. Oncogene 1989;4(5):575-81.
38. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA. 1988;85(23):9268-72.
39. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21): 2159-69.
40. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115 (2):289-95.
41. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-23.
42. Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res. 2009;15(1):30-8.